This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma.

The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules.

The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever.

To learn more about the topics in this episode: 
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
House passes bill directing FDA to update animal testing rules

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma.
The episode covers GSK&rsquo;s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences&rsquo; unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House&rsquo;s passage of legislation directing the FDA to update its animal testing rules.
The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/gsk-secures-first-ever-lung-cancer-fda-approval-jideytro-nuvalent-deal">GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/axiom-plans-head-nasdaq-hong-kong">&lsquo;There is always a first&rsquo;: Why US biotech Axiom will begin its IPO journey in Hong Kong</a></li>
<li><a href="https://www.fiercebiotech.com/cro/us-house-passes-bill-direct-fda-update-clinical-trial-regulations-and-allow-non-animal-testing">House passes bill directing FDA to update animal testing rules</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

GSK’s first lung cancer approval, a new IPO path and more

Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In this episode of The Top Line, Zahiah “Zee Zee” Gueddar, senior director of commercial strategy for the Clinical Trial Financial Suite at IQVIA Technologies, discusses why modernizing clinical trial finance has become a strategic priority for sponsors.

As trials become more complex, fragmented systems and manual workflows are creating bottlenecks that limit visibility, delay payments and introduce unnecessary risk. Gueddar explains how these challenges affect site relationships, operational efficiency and study performance, and why organizations can no longer afford to treat finance as a disconnected administrative process.

The conversation also highlights key indicators of readiness for transformation, from cross-functional alignment to executive sponsorship, and outlines the common pain points study teams face today. Ultimately, success depends on moving toward a connected, transparent and predictable financial model that reduces friction, improves collaboration and supports faster, more reliable clinical trials.

Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In this episode of The Top Line, Zahiah &ldquo;Zee Zee&rdquo; Gueddar, senior director of commercial strategy for the Clinical Trial Financial Suite at IQVIA Technologies, discusses why modernizing clinical trial finance has become a strategic priority for sponsors.
As trials become more complex, fragmented systems and manual workflows are creating bottlenecks that limit visibility, delay payments and introduce unnecessary risk. Gueddar explains how these challenges affect site relationships, operational efficiency and study performance, and why organizations can no longer afford to treat finance as a disconnected administrative process.
The conversation also highlights key indicators of readiness for transformation, from cross-functional alignment to executive sponsorship, and outlines the common pain points study teams face today. Ultimately, success depends on moving toward a connected, transparent and predictable financial model that reduces friction, improves collaboration and supports faster, more reliable clinical trials.

Why modern clinical trials need a finance-first strategy (Sponsored)

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Will Maddox discuss a new Fierce special report identifying five cities with the potential to become major forces in the global biotech industry. Did your favorite city make the cut? Listen to find out. 

To learn more about the topics in this episode: 


Top emerging biotech hubs in 2026 


As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ 


British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize 


Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game 

This week's episode is sponsored by IQVIA Biotech.

 
Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; Fierce Biotech&rsquo;s Darren Incorvaia and Will Maddox discuss a new Fierce special report identifying five cities with the potential to become major forces in the global biotech industry. Did your favorite city make the cut? Listen to find out.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li>
<a href="https://www.fiercebiotech.com/special-reports/top-emerging-biotech-hubs-2026">Top emerging biotech hubs in 2026</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/us-lawmakers-increase-scrutiny-chinese-trials-industry-fears-huge-distraction-and-expense">As US lawmakers increase scrutiny of Chinese trials, industry fears &lsquo;huge distraction and expense&rsquo;</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/british-biotech-vc-funding-shows-signs-recovery-ipo-rebound-yet-materialize">British biotech VC funding shows &lsquo;signs of recovery,&rsquo; but IPO rebound yet to materialize</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/could-basel-be-next-boston-swiss-biotech-hub-raising-its-game">Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game</a>&nbsp;
</li>
</ul>
This week's episode is sponsored by <a href="https://www.iqviabiotech.com/">IQVIA Biotech.</a>
&nbsp; Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit <a href="https://url.us.m.mimecastprotect.com/s/1v3CCQWBXRslR28JsxfOUGfiN5?domain=iqviabiotech.com/">IQVIABiotech.com</a>

5 emerging biotech hubs

AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson, senior vice president of human sciences at The Directions Group, challenges leaders to look beyond AI adoption and focus on the discipline required to act on intelligence.

Masterson argues that the defining issue for many organizations is not a data problem, but a decision readiness problem. As information ecosystems become more complex, the ability to translate insight into timely, confident action is emerging as a critical business differentiator.

With more than 20 years of experience in healthcare and human sciences, Masterson shares perspective on how companies can align teams, processes and strategies to unlock AI’s value without becoming overwhelmed by the volume of available information.

For leaders navigating new technologies, competing priorities and higher expectations for speed, this conversation offers a practical reframing of where AI value is created. Learn why decision readiness may be the next true advantage.

AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson, senior vice president of human sciences at The Directions Group, challenges leaders to look beyond AI adoption and focus on the discipline required to act on intelligence.
Masterson argues that the defining issue for many organizations is not a data problem, but a decision readiness problem. As information ecosystems become more complex, the ability to translate insight into timely, confident action is emerging as a critical business differentiator.
With more than 20 years of experience in healthcare and human sciences, Masterson shares perspective on how companies can align teams, processes and strategies to unlock AI&rsquo;s value without becoming overwhelmed by the volume of available information.
For leaders navigating new technologies, competing priorities and higher expectations for speed, this conversation offers a practical reframing of where AI value is created. Learn why decision readiness may be the next true advantage.

GSK’s first lung cancer approval, a new IPO path and more

The Top Line

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips